Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...
ORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial ...
New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...
Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...
Following a low-carb diet may potentially help patients manage disease more effectively and reduce medication use. Study: Effects of a Carbohydrate-Restricted Diet on β-Cell Response in Adults With ...
1d
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference appearance featuring CEO Mick Hitchcock and COO Ramses Erdtmann. The company ...
The old antihypertensive drug verapamil may help reduce insulin requirements and hypoglycemic episodes in adults with type 1 diabetes, new research suggests. Results from the study were published ...
Please provide your email address to receive an email when new articles are posted on . Greater weight loss at 1 year with tirzepatide improved the odds for sustaining an HbA1c of 6.5% or less at 2 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A restricted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results